Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase–activated protein kinase 5 (MAPKAPK5), also known as PRAK, is a serine/threonine-protein kinase and a member of the MAPKAP kinase subfamily. It acts as a tumor suppressor serine/threonine-protein kinase involved in mTORC1 signaling and post-transcriptional regulation. It is activated by cellular stress and proinflammatory cytokines and phosphorylates several substrates including heat shock protein HSP27, FOXO3, ERK3/MAPK6, and ERK4/MAPK4. It plays roles in cellular stress response pathways and regulation of cell motility. Loss or reduced activity may contribute to cancer progression, and reduced levels have been linked with Alzheimer's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase–activated protein kinase 5 (MAPKAPK5).